ARTICLE | Company News
Bellus Health, Thallion deal
July 29, 2013 7:00 AM UTC
The companies amended the contingent value right (CVR) portion of Bellus' planned acquisition of infectious disease company Thallion. Each CVR is now worth C$0.22, up from C$0.21, thus increasing the ...